news
Novartis announces the appointment of Bruno Strigini as President of Novartis Oncology
2 June 2014 | By Novartis
Novartis announced the appointment of Bruno Strigini, as President of Novartis Oncology...
List view / Grid view
Novartis
news
Novartis provides update on EU marketing authorization application for RLX030 in acute heart failure
23 May 2014 | By Novartis
Novartis announced that the Committee for Medicinal Products for Human Use has adopted a negative opinion for the use of RLX030 in the treatment of acute heart failure...
news
Novartis presents key advances in cancer research at ASCO and EHA from four new pivotal studies in lung, blood and skin cancers
22 May 2014 | By Novartis
Novartis will showcase the results of research efforts to target disease pathways with more than 150 abstracts at two upcoming cancer-focused meetings...
news
Novartis announces positive results at ATS for once-daily Ultibro® Breezhaler® versus combination therapy (tiotropium plus formoterol)
21 May 2014 | By Novartis
Novartis announced new data from the QUANTIFY study, which demonstrated the non-inferiority of Ultibro® Breezhaler® (indacaterol/glycopyrronium) 110/50 mcg compared to tiotropium 18 mcg plus formoterol 12 mcg...
news
Novartis announces exclusive agreement to extend leadership in ophthalmology, leveraging novel anti-PGDF therapy Fovista®
20 May 2014 | By Novartis
Novartis announced the signing of a licensing and commercialization agreement with Ophthotech Corporation for the exclusive rights to market Fovista® outside the United States...
news
FDA issues Complete Response Letter for RLX030 for acute heart failure
16 May 2014 | By Novartis
Novartis announced that the US Food and Drug Administration has issued a Complete Response Letter regarding the Biologics License Application for RLX030...
news
Novartis settles patent litigation on Gleevec® (imatinib mesylate) with Sun Pharma subsidiary
15 May 2014 | By Novartis
Novartis Pharmaceuticals Corporation has settled its litigation with the United States subsidiary of Sun Pharmaceutical Industries Ltd. relating to Novartis patents covering the use of certain polymorphic forms of Gleevec®...
news
Novartis drug Signifor® LAR shows superior efficacy in acromegaly patients not controlled on first generation somatostatin analogues
6 May 2014 | By Novartis
Novartis presented results from a pivotal Phase III trial of investigational therapy Signifor® LAR in patients with acromegaly for whom current standard of care provides inadequate disease control...
news
Novartis’ INSTEAD study for Onbrez® Breezhaler® in patients with moderate COPD meets primary objective
25 April 2014 | By Novartis
Novartis announced top-line results from the Phase IV INSTEAD switch study in patients with chronic obstructive pulmonary disease, which met its primary objective...
news
Novartis announces portfolio transformation, focusing company on leading businesses with innovation power and global scale: Pharmaceuticals, Eye Care and Generics
22 April 2014 | By Novartis
Novartis announced that it has reached a definitive agreement with GlaxoSmithKline plc to exchange certain assets, building global leadership in key segments and focusing the company's portfolio...
news
GSK plc announces major three-part transaction with Novartis to drive sustainable sales growth, improve long-term earnings and deliver increasing returns to shareholders
22 April 2014 | By GlaxoSmithKline
GlaxoSmithKline plc announces a major 3-part inter-conditional transaction with Novartis AG involving its Consumer Healthcare, Vaccines and Oncology businesses...
news
Novartis appoints Jeff George as Division Head, Alcon as Kevin Buehler retires; Richard Francis named as new Division Head, Sandoz
9 April 2014 | By Novartis
Novartis announced the appointment of Jeff George as Division Head of Alcon, effective May 1, 2014...
news
Novartis and Malaria No More provide two million antimalarial treatments to children in Zambia
7 April 2014 | By Novartis
Novartis announced that two million treatments of its pediatric antimalarial are arriving in Zambia thanks to the ongoing efforts of the company in collaboration with Malaria No More's Power of One campaign...
news
Novartis data on 19 compounds at AACR highlight strong cancer pipeline across multiple molecular targets and biological pathways
4 April 2014 | By Novartis
Novartis announced that early stage data on 19 investigational compounds in its oncology pipeline will be presented at the annual meeting of the American Association of Cancer Research...
news
PARADIGM-HF trial of Novartis’ LCZ696 for chronic heart failure closes early based on strength of interim results
31 March 2014 | By Novartis
Novartis announced that the Data Monitoring Committee unanimously recommended early closure of the PARADIGM-HF study...
